CD274 and non-small cell lung carcinoma: The treatment for NSCLC underwent transformation through the advent of targeted therapies and the emergence of immune checkpoint inhibitors (ICIs), particularly monoclonal antibodies against PD‐1 and PD‐L1.2, 3